In our research, we utilized the Clustered Regularly Interspaced Short Palindromic Repeats interference (CRISPRi) system to suppress PD-L1 expression on breast cancer cells (4T1) and combined it with epigenetic inhibitor azacytidine (AZA) for enhanced cancer immunotherapy. Here, CD274 is linked to breast carcinoma.